A Working Definition
The Neuroeconomy is the economic regime in which the primary determinant of individual and aggregate productivity is cognitive capacity rather than physical capacity. In a neuroeconomy, the value a person produces is bounded by the function of their brain: attention, working memory, executive control, learning rate, decision quality, emotional regulation, and resilience under load. When those functions are intact, the individual operates close to their economic ceiling. When they degrade, productivity falls, and the rate of fall accelerates with age. Brain function is the asset, and it is also the asset most rapidly being depleted by the conditions of modern work.
We use this term in a specific clinical and economic sense, distinct from the academic field of neuroeconomics, which studies the neural basis of decision-making in laboratory settings. The Neuroeconomy we are describing is the world the patient walks out of our exam room into: an economy whose returns are gated by cognitive function.
The shift to a neuroeconomy is not a future event. It already happened. The institutions that price labor, the policies that govern healthcare, and the medical models we use to manage cognitive decline have not caught up. That mismatch is producing measurable damage to the population whose brains generate disproportionate economic output.
How We Got Here
For most of human economic history, the binding constraint on individual productivity was physical: how much a person could lift, plow, hammer, walk, or carry. Wages tracked muscle. Class systems were organized around physical labor as the bottom rung. Medicine was organized around keeping bodies functional enough to work, and public health gained against tuberculosis and dysentery because keeping a body alive at twenty-five and productive at fifty was the central economic problem.
The cardio-industrial economy, as we'll call it, persisted through the late twentieth century. Manufacturing, agriculture, construction, and transport accounted for the majority of GDP in the developed world as recently as 1950. The body was the asset.
That economy hollowed out faster than most clinicians appreciate. By 2024, the U.S. Bureau of Labor Statistics reported that manufacturing employment had fallen below 8% of the workforce. Agriculture sat below 1.5%. Construction stayed near 5%. The expansion came in cognitively loaded sectors: information work, finance, professional services, healthcare administration, software, education, design. Those sectors now account for the majority of value created in developed economies, and the people working in them are paid for what their brains can do, not what their bodies can do.
The transition was never announced. It happened gradually, then suddenly, the way most regime shifts happen. By the time anyone noticed, the institutions built for the previous economy were still running, and the new economy had no infrastructure built for its primary asset.
The Brain as an Economic Asset
Treat the brain the way you would treat any other asset that compounds returns over time. It has a depreciation schedule, a maintenance cost, a peak operating range, and a failure mode. Most physicians are trained to manage the failure mode, meaning stroke, dementia, and traumatic injury, and to ignore everything before it. In the cardioeconomy that was rational triage. In the neuroeconomy it is neglect.
Three properties of the brain as an economic asset are worth naming.
The brain compounds
Cognitive capacity invested early returns disproportionately over decades. A thirty-five-year-old who protects sleep, manages cardiovascular risk factors, learns continuously, and titrates chronic stress is not merely healthier than a peer who doesn't. They are accumulating an asset whose returns are nonlinear. The compounding maps closely to the compounding of capital in financial markets, where small consistent contributions sustained over decades dominate large one-time interventions late in life.
The brain depreciates predictably under load
The neural systems responsible for executive function, working memory, and emotional regulation are the systems most sensitive to chronic stress, sleep deprivation, metabolic dysregulation, and inflammatory load. They are also the systems most central to the work modern economies demand. The Neuroeconomy is structurally built around tasks that maximize wear on the brain regions most responsible for the work itself. That is the central paradox of the new economy: the way it is currently organized destroys the asset that produces its value.
The brain has a failure mode that other assets do not
A failing car, a failing roof, and a failing balance sheet all announce themselves. The brain does not. The neural regions responsible for noticing your own cognitive decline are the same regions that decline first under chronic stress. We return to this below, because it is the single most economically dangerous feature of the asset.
Brain Fitness, Defined
The cardioeconomy produced a concept the public learned to recognize: cardiovascular fitness. We built infrastructure around it. Gyms. Heart-rate monitors. VO2 max as a metric. Risk stratification by lipid panels and blood pressure. Wearables that measure recovery. The cultural and clinical literacy around cardiovascular fitness took fifty years to mature.
Brain Fitness is the analogous concept for the neuroeconomy. We define it as the brain's capacity to meet cognitive and emotional demand without performance degradation, sustained across the productive lifespan. It rests on four measurable substrates.
Neurotransmitter availability and dynamics
Dopamine, acetylcholine, serotonin, GABA, glutamate, and norepinephrine govern attention, learning, mood, and stress response. These systems are depletable. Chronic stress, poor sleep, certain medications, and sustained substance use all reduce the brain's capacity to produce, store, and release them.
Metabolic capacity
The brain consumes 20% of basal metabolic rate. Sustained cognitive work generates metabolic byproducts, including misfolded proteins such as tau and beta-amyloid, that must be cleared by the glymphatic system during sleep. Disrupted sleep, sleep apnea, and insulin resistance all impair that clearance, and failure to clear results in the slow accumulation of pathological burden that becomes the substrate of late-life dementia.
Structural integrity
White matter tracts connect brain regions, and both chronic stress and vascular disease damage them. Reduced white matter integrity produces slowed processing, impaired emotional regulation, and decreased cognitive flexibility. Volumetric MRI can measure this decline in vivo, and diffusion tensor imaging can detect it earlier than standard MRI.
Vascular health
The brain receives 15% of cardiac output. Hypertension, atherosclerosis, sleep apnea, sedentary behavior, and chronic inflammation each compromise cerebral perfusion, and even subclinical reductions in perfusion produce measurable cognitive degradation over time. The cardiovascular system is not a separate domain from cognitive function. It is one of cognitive function's primary inputs.
A patient with intact Brain Fitness can sustain high cognitive demand for years without degradation. A patient whose Brain Fitness has declined cannot, no matter how strong their willpower or how high their initial intelligence.
The Three Stages of Burnout
What clinicians call burnout is a neurobiological trajectory that proceeds through identifiable stages. It is not a personality problem, a discipline problem, or a moral failure. It is a sequential degradation of the substrates named above, and it is the most common route by which a working brain arrives at brain failure.
Stage one: dysregulation
The brain is operating at or near capacity. Sleep architecture begins to fragment and the prefrontal cortex cannot fully disengage at night. Working memory degrades subtly. Emotional reactivity increases. The patient often still performs well at work, but that performance is now coming from depleted reserves rather than abundant supply. They are functional and tired. Bloodwork in this stage often shows mildly elevated cortisol, slightly disrupted thyroid markers, and reduced heart rate variability on wearable trackers. This stage is highly modifiable, and the interventions are sleep, cardiovascular conditioning, stress titration, and metabolic optimization.
Stage two: compensation failure
Maladaptive strategies emerge. Procrastination appears as the prefrontal cortex fails at executive planning. Anhedonia appears as dopaminergic depletion blunts reward signaling. Alcohol, stimulants, cannabis, or anxiolytics appear as self-medication for a dysregulation the patient cannot otherwise resolve. Many patients enter clinical care at this stage, because they still retain enough executive function to recognize that something is wrong. Intervention works here, but it requires a longer time horizon and more aggressive metabolic and neurochemical support. NAD+ and methylated B-vitamin protocols, sleep architecture restoration, and targeted neuromodulation all become part of the picture.
Stage three: system collapse
The compensatory mechanisms have exhausted themselves. The patient presents with severe depression, complete cognitive disengagement, suicidal ideation, or sometimes an acute psychiatric emergency. Some patients do not return to their prior cognitive baseline. This is the stage at which insurance reliably engages, by which time the marginal cost per unit of recovered function is at its highest and the probability of full recovery is at its lowest.
Each stage is preventable by addressing the one before it. The cost differential between a stage one intervention and a stage three intervention runs to several orders of magnitude, and the opportunity cost, meaning what the patient could have produced had someone intervened at stage one, is often larger than the direct medical cost.
The reason patients reach stage three in such numbers is the structural feature we take up next.
Anosognosia and the Asset That Cannot Watch Itself
Anosognosia is the clinical term for unawareness of one's own neurological deficit. It is classically described in stroke, traumatic brain injury, and certain forms of dementia. It is also present, in milder but functionally consequential forms, in burnout, chronic sleep deprivation, and early cognitive decline.
The mechanism is clinically established. The brain regions responsible for monitoring your own cognitive function are concentrated in the prefrontal cortex and the anterior insula, and those are the same regions that show degraded function under chronic stress. As your capacity declines, your capacity to notice the decline declines with it.
The economic implication is severe. The Neuroeconomy is a regime in which the primary asset cannot reliably evaluate its own condition. Patients in stage one and stage two burnout consistently report that they feel fine, even as objective measures of their cognitive performance show clear degradation. Their families notice. Their colleagues notice. The patient does not.
That makes external assessment essential rather than optional. Subjective self-report of cognitive function is unreliable, so a real brain workup in a high-functioning, cognitively demanding professional should include objective neuropsychological testing, biomarker panels covering inflammatory and metabolic markers, sleep architecture assessment, and volumetric brain imaging. Each of those measures something the patient cannot assess from the inside.
The cardioeconomy analog is the executive physical. We do not ask a fifty-five-year-old executive whether his heart is working well. We do an EKG, a stress test, a lipid panel, and an echocardiogram. The Neuroeconomy demands the same posture for the brain, and most healthcare systems are not yet built to deliver it.
What Brain Stewardship Looks Like
Brain stewardship is the deliberate, evidence-based management of the brain as a long-duration economic asset. It is not biohacking and it is not wellness theater. It is the application of clinical neuroscience to the daily reality of working in a cognitively demanding environment, and it rests on seven anchors.
Sleep is the most modifiable substrate. Seven to nine hours nightly with consistent timing, screened for sleep apnea, optimized for slow-wave and REM proportions. The cost of chronic sleep deprivation on cognitive performance is empirically larger than the cost of any other modifiable input. A high-performing professional who sleeps six hours nightly is functionally operating below their cognitive ceiling, and the gap compounds.
Cardiovascular conditioning is the second anchor. Thirty to forty-five minutes of aerobic exercise four to five times weekly produces measurable improvements in cerebral perfusion, glymphatic clearance, brain-derived neurotrophic factor signaling, and hippocampal volume. The 2026 Nature Aging trial of 150 minutes of weekly cardio in midlife adults documented a measurable reduction in brain age over twelve months. The mechanism is not fully BDNF-mediated, as vascular remodeling and inflammatory regulation both contribute.
Metabolic regulation is the third. Insulin sensitivity, glucose variability, lipid handling, and visceral adiposity all affect brain function. The increasingly recognized concept of Type 3 diabetes, meaning insulin resistance in the central nervous system, connects metabolic dysfunction to Alzheimer's-pattern neurodegeneration through pathways that include impaired cortical glucose utilization and increased neuroinflammation. Metabolic optimization is brain optimization.
Stress titration is the fourth. The brain does not adapt well to chronic uniform stress; it adapts to varied stress with adequate recovery. Strategic recovery periods, deliberate mental rest, and the reduction of decision fatigue all produce measurable improvements in executive function. Wearable heart rate variability data tracks this in close to real time and serves as a reasonable proxy for cognitive recovery state.
Cognitive challenge with adequate novelty is the fifth. Continuous learning, deliberate skill acquisition, and graded difficulty maintain neuroplastic capacity. The brain that does not encounter novelty contracts, and the brain that does expands. A patient whose work has become rote needs deliberate cognitive load outside of work to maintain plastic capacity.
Relational investment is the sixth. Secure attachment relationships measurably buffer the cortisol response to stress and support prefrontal function. Social isolation in midlife is now established as an independent risk factor for late-life dementia, with effect sizes comparable to hypertension. The relational dimension of brain stewardship is not optional.
Regular objective assessment is the seventh, and it returns us to the anosognosia problem. Volumetric brain MRI with normative comparison every two to three years. Cognitive testing at baseline and at intervals. Biomarker panels including p-tau217, the most accurate Alzheimer's blood biomarker now in clinical use, along with folate receptor antibodies, homocysteine, and inflammatory markers. None of these are exotic. They are simply not standard practice, because the framing that would make them standard, the brain as a managed asset, is not yet built into the system.
Nutritional support belongs inside these anchors rather than alongside them. The compounds that matter most for a depleted brain, NAD+ precursors, methylated B vitamins, and omega-3 fatty acids among them, are worth discussing with a clinician who knows your biomarker panel, which is the approach we take through Action Potential Supplements. A supplement protocol chosen without that panel is guesswork.
The Clinical Implications of a Neuroeconomy
Three implications follow directly from this framing.
The first is that wellness and performance stop being separable concepts. In the cardioeconomy, a successful executive could maintain modest cardiovascular health and still perform economically. In the neuroeconomy, the executive whose Brain Fitness has degraded cannot perform at the level the role requires. Wellness becomes a precondition for productivity rather than a luxury alongside it.
The second is that the relevant time horizon for clinical care lengthens. A standard primary care visit measures health on a one-year cycle, while brain stewardship operates on a twenty-year cycle. The diagnostic and therapeutic tools that catch decline early enough to matter require a different posture: longitudinal tracking, baseline assessment, programmed reassessment. A practice built on a twenty-year cycle looks nothing like a practice built on a one-year cycle, which is why we structured the Intensive Brain Health Program around the longer horizon.
The third is that the economic case for premium brain care strengthens with each year the neuroeconomy deepens. The cost of brain failure in a fifty-year-old professional is not measured in medical bills. It is measured in foregone earnings, foregone strategic decisions, and foregone relationships. The dollar value of a year of intact executive function in a leadership role can run into seven figures, and the cost of a precision brain workup is a small fraction of that. The math becomes obvious once the framing shifts.
What This Means for You
The patient in the neuroeconomy is the person whose work depends on attention, judgment, learning, and resilience. That is, increasingly, every working adult above a certain income threshold. The relevant question is not whether your brain is healthy enough. The relevant question is whether your brain is operating close to its ceiling, and what is changing year over year.
Most patients never get an answer, because most healthcare systems were not built to provide one. They were built for the cardioeconomy, where the brain was a secondary concern until something acute went wrong with it. If you are in a cognitively demanding role and you have never had objective cognitive testing, a volumetric MRI, or a biomarker panel that goes beyond a standard metabolic screen, you have no baseline. Without a baseline, neither you nor your physician can distinguish normal variation from the early slope of decline, and by the time the difference is obvious without testing, you are further along the trajectory than you needed to be.
The practical move is to establish that baseline while you still feel fine. Feeling fine is not evidence, for the reason described above. Ask your physician what objective measures of your cognitive function exist in your chart. If the answer is none, that is the gap.
The Neuroeconomy is already here. The framing is what has to catch up, and this piece is part of that framing.
A Closing Note on the Framing
We did not invent the underlying observation. Labor economists have documented the shift from a physical-labor economy to a cognitive-labor economy for thirty years. What we are doing here is giving that shift a clinical name, attaching it to a specific set of medical implications, and arguing that clinical practice has to change in response. Our earlier essay, Welcome to the Neuroeconomy, introduced the idea; this piece is the formal definition.
If the term sticks, it will be because the medical model it implies delivers measurably better outcomes for the population it describes. The argument is not rhetorical. It is empirical, and the data are accumulating. We will update this piece as they do.
Sean C. Orr, M.D., is Chief Medical Officer and Co-Founder of The Neurogenesis Project. Drew W. Edwards, Ed.D, M.S., is Chief Clinical Officer and Co-Founder.